MPM BioImpact’s argenx ARGX Stock Holding History

MPM BioImpact’s Portfolio ARGX Stock Details ARGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-71,700	Closed	-$11.5M	–	11
2019 Q4	$11.5M	Buy	+71,700	New	+$9.7M	4.08%	8

Other funds holding ARGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MPM BioImpact's ARGX Position: Q1 2020 in Review

MPM BioImpact sold out of argenx (ARGX) in Q1 2020, closing a stake of 71,700 shares — an estimated $11.5M sold.

MPM BioImpact first reported a position in ARGX in Q4 2019 and held it in 1 quarter. The position peaked at $11.5M in Q4 2019. 143 funds tracked by Wall St. Rank hold ARGX as of Q1 2020.

MPM BioImpact reported no remaining argenx position as of Q1 2020 after selling out during the quarter.
MPM BioImpact sold 71,700 argenx shares in Q1 2020, an estimated $11.5M.
MPM BioImpact first reported a position in argenx in Q4 2019 and held it in 1 quarter.
MPM BioImpact's argenx position peaked at $11.5M in Q4 2019.
143 funds tracked by Wall St. Rank held argenx as of Q1 2020.

Based on MPM BioImpact's 13F filing for Q1 2020, filed 13 May 2020.